drozitumab

{{Short description|Monoclonal antibody}}

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 458638503

| type = mab

| image =

| alt =

| mab_type = mab

| source = u

| target = DR5

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 912628-39-8

| ATC_prefix = none

| ATC_suffix =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = SQ67484MA7

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| C=6334 | H=9792 | N=1700 | O=2000 | S=42

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| KEGG_Ref = {{keggcite|changed|kegg}}

| KEGG = D09888

}}

Drozitumab is a human monoclonal antibody in development for the treatment of cancers.{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Drozitumab|publisher=American Medical Association|url=http://www.ama-assn.org/resources/doc/usan/drozitumab.pdf}}{{cite journal | vauthors = Micheau O, Shirley S, Dufour F | title = Death receptors as targets in cancer | journal = British Journal of Pharmacology | volume = 169 | issue = 8 | pages = 1723–1744 | date = August 2013 | pmid = 23638798 | pmc = 3753832 | doi = 10.1111/bph.12238 }} It targets Tumour Necrosis Factor Related Apoptosis-inducing Ligand (TRAIL), whose receptors are found on the surface of many types of malignant cells.{{cite journal | vauthors = Gasparini C, Vecchi Brumatti L, Monasta L, Zauli G | title = TRAIL-based therapeutic approaches for the treatment of pediatric malignancies | journal = Current Medicinal Chemistry | volume = 20 | issue = 17 | pages = 2254–2271 | date = 2013 | pmid = 23458616 | doi = 10.2174/0929867311320170009 }} Drozitumab was developed by Genentech.

Although drozitumab was studied in phase II trials for treating chondrosarcoma, colorectal cancer, non-Hodgkin lymphoma, and non-small cell lung cancer, development has been halted due to lack of clinical response.{{cite web|title=Drozitumab|url=http://adisinsight.springer.com/drugs/800025104|website=AdisInsight|access-date=31 January 2017}}